Literature DB >> 10070117

Inducible NO synthase inhibition attenuates shear stress-induced pulmonary vasodilation in the ovine fetus.

R L Rairigh1, L Storme, T A Parker, T D le Cras, J P Kinsella, M Jakkula, S H Abman.   

Abstract

Recent studies have suggested that type II (inducible) nitric oxide (NO) synthase (NOS II) is present in the fetal lung, but its physiological roles are uncertain. Whether NOS II activity contributes to the NO-mediated fall in pulmonary vascular resistance (PVR) during shear stress-induced pulmonary vasodilation is unknown. We studied the hemodynamic effects of two selective NOS II antagonists [aminoguanidine (AG) and S-ethylisothiourea (EIT)], a nonselective NOS antagonist [nitro-L-arginine (L-NNA)], and a nonselective vasoconstrictor (U-46619) on PVR during partial compression of the ductus arteriosus (DA) in 20 chronically prepared fetal lambs (mean age 132 +/- 2 days, term 147 days). At surgery, catheters were placed in the left pulmonary artery (LPA) for selective drug infusion, an ultrasonic flow transducer was placed on the LPA to measure blood flow, and an inflatable vascular occluder was placed loosely around the DA for compression. On alternate days, a brief intrapulmonary infusion of normal saline (control), AG, EIT, L-NNA, or U-46619 was infused in random order into the LPA. The DA was compressed to increase mean pulmonary arterial pressure (MPAP) 12-15 mmHg above baseline values and held constant for 30 min. In control studies, DA compression reduced PVR by 42% from baseline values (P < 0.01). L-NNA treatment completely blocked the fall in PVR during DA compression. AG and EIT attenuated the decrease in PVR by 30 and 19%, respectively (P < 0.05). Nonspecific elevation in PVR by U-46619 did not affect the fall in PVR during DA compression. Immunostaining for NOS II identified this isoform in airway epithelium and vascular smooth muscle in the late-gestation ovine fetal lung. We conclude that selective NOS II antagonists attenuate but do not block shear stress-induced vasodilation in the fetal lung. We speculate that stimulation of NOS II activity, perhaps from smooth muscle cells, contributes in part to the NO-mediated fall in PVR during shear stress-induced pulmonary vasodilation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10070117     DOI: 10.1152/ajplung.1999.276.3.L513

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  6 in total

Review 1.  Sex differences in the pulmonary circulation: implications for pulmonary hypertension.

Authors:  Yvette N Martin; Christina M Pabelick
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-03-07       Impact factor: 4.733

2.  Fetal ventricular interactions and wall mechanics during ductus arteriosus occlusion in a sheep model.

Authors:  Jason N Hashima; Vanessa Rogers; Stephen M Langley; Muhammed Ashraf; David J Sahn; Pasi Ohtonen; Lowell E Davis; A Roger Hohimer; Juha Rasanen
Journal:  Ultrasound Med Biol       Date:  2015-02-17       Impact factor: 2.998

3.  Changes in functional and histological distributions of nitric oxide synthase caused by chronic hypoxia in rat small pulmonary arteries.

Authors:  Mikiyasu Shirai; James T Pearson; Akito Shimouchi; Noritoshi Nagaya; Hirotsugu Tsuchimochi; Ishio Ninomiya; Hidezo Mori
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

4.  Possible involvement of nitric oxide and peroxynitrite in the pathogenesis of human vocal polyps and nodules.

Authors:  Bor-Hwang Kang; Ming-Wang Hsiung; Hsing-Won Wang
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-03-11       Impact factor: 2.503

Review 5.  Modulation of pulmonary vasomotor tone in the fetus and neonate.

Authors:  N S Ghanayem; J B Gordon
Journal:  Respir Res       Date:  2001-03-08

6.  Cyclic stretch induces inducible nitric oxide synthase and soluble guanylate cyclase in pulmonary artery smooth muscle cells.

Authors:  Monica R Shah; Stephen Wedgwood; Lyubov Czech; Gina A Kim; Satyan Lakshminrusimha; Paul T Schumacker; Robin H Steinhorn; Kathryn N Farrow
Journal:  Int J Mol Sci       Date:  2013-02-21       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.